Diaceutics Share Price, News & Analysis (LON:DXRX) GBX 92 0.00 (0.00%) (As of 12/8/2023 ET) Add Compare Share Share Today's Range 90▼ 92.5050-Day Range 83.15▼ 10552-Week Range 74▼ 118Volume6,167 shsAverage Volume54,748 shsMarket Capitalization£77.73 millionP/E Ratio10,500.00Dividend YieldN/APrice TargetGBX 150 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesInsider TradesStock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesInsider Trades About Diaceutics Stock (LON:DXRX)Diaceutics PLC, a diagnostic commercialisation company, provides data, data analytics, and implementation services for pharmaceutical companies worldwide. It operates DXRX platform, which offers DXRX data solutions, including access to various pipelines of diagnostic testing data from a network of laboratories that provides DXRX signal, lab mapping, testing dashboard, and physician mapping services; DXRX marketplace solutions, which enables a marketplace, where labs, pharma, and diagnostic companies come to find partners for collaborations on precision medicine diagnostics. The company also provides DXRX lab education, a suite of tailored and targeted training sessions designed to provide essential education for labs to enable and drive quality testing and biomarker knowledge; DXRX advisory boards that create and enable a valuable interface for pharmaceutical companies with a view to exploring and revealing new insights pertinent to the commercialisation and development of a therapy or companion diagnostic; and DXRX Lab Alerts, an advanced laboratory targeting service delivering tailored, short-form, quick read, educational messages with call-to-action to labs in the DXRX network. In addition, it offers implementation and consulting services for precision medicine diagnostics. Diaceutics PLC was incorporated in 2005 and is headquartered in Belfast, the United Kingdom.Read More DXRX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart DXRX Stock News HeadlinesOctober 26, 2023 | finance.yahoo.comDiaceutics (LON:DXRX) shareholders have endured a 41% loss from investing in the stock three years agoOctober 26, 2023 | finance.yahoo.comDiaceutics First Half 2023 Earnings: EPS Beats ExpectationsDecember 9, 2023 | Autonomix (Ad)[Investor Alert] Potential Breakthrough Medical Tech Investment OpportunityAutonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comOctober 26, 2023 | finance.yahoo.comCalculating The Intrinsic Value Of Diaceutics PLC (LON:DXRX)April 20, 2023 | finance.yahoo.comDiaceutics PLC (LON:DXRX) Stock Is Going Strong But Fundamentals Look Uncertain: What Lies AheadApril 20, 2023 | finance.yahoo.comDiaceutics PLC (LON:DXRX) Stock Is Going Strong But Fundamentals Look Uncertain: What Lies Ahead ?April 17, 2023 | marketwatch.comDiaceutics 2022 Pretax Profit Rose on Growing DemandMarch 13, 2023 | marketwatch.comDiaceutics Suspends Share Trading as SVB Closure Restricts Access to Its FundsDecember 9, 2023 | Autonomix (Ad)[Investor Alert] Potential Breakthrough Medical Tech Investment OpportunityAutonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comMarch 10, 2023 | finance.yahoo.comThose who invested in Diaceutics (LON:DXRX) a year ago are up 13%January 28, 2023 | finance.yahoo.comBroker Revenue Forecasts For Diaceutics PLC (LON:DXRX) Are Surging HigherJanuary 27, 2023 | lse.co.ukTRADING UPDATES: Diaceutics wins two deals; Faron proposes placingDecember 9, 2022 | finance.yahoo.comAn Intrinsic Calculation For Diaceutics PLC (LON:DXRX) Suggests It's 40% UndervaluedNovember 28, 2022 | msn.comDanske Bank supported the purchase of the new building at Kings Hall Life Sciences ParkSeptember 29, 2022 | finance.yahoo.comEdited Transcript of DXRX.L earnings conference call or presentation 28-Sep-22 12:00pm GMTSeptember 16, 2022 | nz.finance.yahoo.comDEWA and WGEO Complete Preparations for 8th Edition of the World Green Economy SummitSeptember 16, 2022 | yahoo.comBake Off star Laura Adlington reveals she was left suicidal after trolls fat-shamed her on social mediaAugust 14, 2022 | uk.finance.yahoo.comDiaceutics PLC (DXRX.L)July 2, 2022 | finance.yahoo.comIs Diaceutics PLC (LON:DXRX) Trading At A 32% Discount?June 13, 2022 | lse.co.ukDiaceutics wins USD2 million contract with "top five global" drug firmMay 23, 2022 | finance.yahoo.comDiaceutics PLC (LON:DXRX) Has Varied Financials: Could That Be Why Its Recent Performance Has Been Uneventful?May 5, 2022 | lse.co.ukDiaceutics inks five-year deal with existing pharma partnerApril 7, 2022 | finance.yahoo.comThe past year for Diaceutics (LON:DXRX) investors has not been profitableMarch 22, 2022 | lse.co.ukDiaceutics returns to pretax profit in 2021 and ups revenueMarch 16, 2022 | marketwatch.comDiaceutics Approved by US Agency to Receive Enhanced DataFebruary 14, 2022 | marketwatch.comDiaceutics Gets Three-Year Contract Worth More Than $2.5 MlnJanuary 25, 2022 | uk.news.yahoo.comIs this FTSE AIM stock primed for growth in 2022?See More Headlines Receive DXRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Diaceutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeLON Industry Diagnostics & Research Sub-IndustryN/A SectorMedical Current SymbolLON:DXRX CUSIPN/A CIKN/A Webwww.diaceutics.com PhoneN/AFaxN/AEmployees151Year FoundedN/APrice Target and Rating Average Stock Price TargetGBX 150 High Stock Price TargetGBX 150 Low Stock Price TargetGBX 150 Potential Upside/Downside+63.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E Ratio10,500.00 Forward P/E Ratio29.58 P/E GrowthN/ANet IncomeN/A Net Margins0.03% Pretax MarginN/A Return on Equity0.01% Return on Assets-0.72% Debt Debt-to-Equity Ratio3.07 Current Ratio7.99 Quick Ratio9.92 Sales & Book Value Annual Sales£21.90 million Price / Sales3.55 Cash FlowGBX 29.49 per share Price / Cash Flow3.12 Book ValueGBX 49 per share Price / Book1.88Miscellaneous Outstanding Shares84,490,000Free FloatN/AMarket Cap£77.73 million OptionableNot Optionable Beta0.45 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesMr. Peter Keeling (Age 62)Founder, CEO & Executive Director Comp: $363.24kMr. Nicholas Stewart Roberts (Age 40)CFO & Director Comp: $180.37kMr. Ryan Keeling (Age 40)Executive Director Comp: $334.27kMs. Julie BrowneChief Operating OfficerMs. Gillian ShawGeneral CounselMs. Norma ThompsonGlobal Head of Human ResourcesMr. Jordan ClarkChief Commercial OfficerMs. Susanne MunkstedChief Precision Medicine OfficerMs. Jillian BeggsChief Commercial OfficerMs. Marieke HoefsmitSenior Director & Head of Data Delivery NetherlandsMore ExecutivesKey CompetitorsANGLELON:AGL4basebioLON:4BBECO Animal Health GroupLON:EAHINSPECS GroupLON:SPECSourcebio InternationalLON:SBIView All CompetitorsInsidersNick RobertsBought 170 shares on 10/27/2023Total: £14,960.00 ($88.00/share)Nick RobertsBought 139 shares on 8/29/2023Total: £139.00 ($1.00/share)Nick RobertsBought 21,742 shares on 6/5/2023Total: £2.00 M ($92.00/share)Nick RobertsBought 183 shares on 5/30/2023Total: £15,006.00 ($82.00/share)Nick RobertsBought 130 shares on 2/28/2023Total: £14,950.00 ($115.00/share)View All Insider Transactions DXRX Stock Analysis - Frequently Asked Questions Should I buy or sell Diaceutics stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Diaceutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" DXRX shares. View DXRX analyst ratings or view top-rated stocks. What is Diaceutics' stock price target for 2024? 2 Wall Street research analysts have issued 1 year price targets for Diaceutics' stock. Their DXRX share price targets range from GBX 150 to GBX 150. On average, they predict the company's share price to reach GBX 150 in the next year. This suggests a possible upside of 63.0% from the stock's current price. View analysts price targets for DXRX or view top-rated stocks among Wall Street analysts. How have DXRX shares performed in 2023? Diaceutics' stock was trading at GBX 75.50 at the start of the year. Since then, DXRX stock has increased by 21.9% and is now trading at GBX 92. View the best growth stocks for 2023 here. How do I buy shares of Diaceutics? Shares of DXRX stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. This page (LON:DXRX) was last updated on 12/9/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Diaceutics PLC Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.